INT126172

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 9.01
Pain Relevance 2.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pla2g4a) Golgi apparatus (Pla2g4a) endoplasmic reticulum (Pla2g4a)
nucleus (Pla2g4a) cytoplasm (Pla2g4a)
Anatomy Link Frequency
spinal cord 2
Pla2g4a (Mus musculus)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 8 99.48 Very High Very High Very High
intrathecal 4 98.84 Very High Very High Very High
Spinal cord 16 98.72 Very High Very High Very High
Brush evoked pain 48 98.52 Very High Very High Very High
Thermal hyperalgesia 2 97.80 Very High Very High Very High
Neuropathic pain 17 97.66 Very High Very High Very High
Arthritis 3 96.70 Very High Very High Very High
Inflammation 122 94.80 High High
dorsal root ganglion 95 93.76 High High
allodynia 5 93.04 High High
Disease Link Frequency Relevance Heat
Apoptosis 37 99.56 Very High Very High Very High
Cancer 22 99.48 Very High Very High Very High
Disease 258 99.16 Very High Very High Very High
Mycobacterial Infection 96 99.04 Very High Very High Very High
Neuropathic Pain 71 98.52 Very High Very High Very High
Targeted Disruption 27 97.92 Very High Very High Very High
Hyperalgesia 3 97.80 Very High Very High Very High
Injury 8 97.32 Very High Very High Very High
Infection 66 96.92 Very High Very High Very High
Arthritis 3 96.70 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immunohistochemistry and real-time RT-PCR revealed elevated cPLA2 protein and its mRNA levels in the lumbar spinal cord of mutant SOD1 mice.
Negative_regulation (revealed) of cPLA2 protein in spinal cord associated with spinal cord
1) Confidence 0.39 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15816863 Disease Relevance 0.91 Pain Relevance 0.27
Sulindac, as well as the selective COX-2 inhibitors, rofecoxib and celecoxib reduced cPLA2 immunoreactivity in the lumbar spinal cord of G93A transgenic mice.
Negative_regulation (reduced) of cPLA2 in spinal cord associated with targeted disruption, cox-2 inhibitor and spinal cord
2) Confidence 0.39 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15816863 Disease Relevance 1.01 Pain Relevance 0.37
Both de novo LPA production and neuropathic pain-like behaviors were substantially abolished by intrathecal injection of arachidonyl trifluoromethyl ketone, a mixed inhibitor of cPLA2 and iPLA2, or bromoenol lactone, an iPLA2 inhibitor, at 1 h after injury.
Negative_regulation (inhibitor) of cPLA2 associated with injury, neuropathic pain and intrathecal
3) Confidence 0.39 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 20123931 Disease Relevance 1.16 Pain Relevance 0.61
In an antigen-induced arthritis model, Cerk-/- mice were not protected, thus inconsistent with the hypothesis that C1P made by CERK is key for cPLA2 activation in vivo -- parallel pharmacological inhibition of cPLA2 could indeed dampen disease development [3].
Negative_regulation (inhibition) of cPLA2 associated with disease and arthritis
4) Confidence 0.21 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2817648 Disease Relevance 0.58 Pain Relevance 0.09
Since our previous study showed that acute inhibition of cPLA2 produces an alleviation of existing tactile allodynia [5], we then examined whether pharmacological blockade of PAFRs and LPARs could also be effective in treating existing allodynia.
Negative_regulation (inhibition) of cPLA2 associated with brush evoked pain and allodynia
5) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2862737 Disease Relevance 1.41 Pain Relevance 1.20
Dietary curcumin at 2,000 ppm, a dose with proven long-term safety by the National Toxicology Program [183], was shown to reduce cPLA2 activity in cancer models in vivo [184].
Negative_regulation (reduce) of cPLA2 associated with cancer
6) Confidence 0.19 Published 2010 Journal Mol Neurobiol Section Body Doc Link PMC2876259 Disease Relevance 0.71 Pain Relevance 0.20
production by increasing BACE [57–60].Anti-ERK and JNK: The mechanism of curcumin's ability to reduce cPLA2 has been investigated in vitro and demonstrated to involve reducing phosphorylation at the same MAPK-sensitive site (ser 505) [182] that is elevated in AD, AD model mice, and A?
Negative_regulation (reduce) of cPLA2 associated with disease
7) Confidence 0.12 Published 2010 Journal Mol Neurobiol Section Body Doc Link PMC2876259 Disease Relevance 0.87 Pain Relevance 0.12
We demonstrated that inhibition of cPLA2 abrogates apoptosis in Mtb-infected M?
Negative_regulation (inhibition) of cPLA2 associated with mycobacterial infection and apoptosis
8) Confidence 0.09 Published 2008 Journal The Journal of Experimental Medicine Section Body Doc Link PMC2585850 Disease Relevance 2.36 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox